Please login to the form below

amyloidosis

This page shows the latest amyloidosis news and features for those working in and with pharma, biotech and healthcare.

23rd PMEA celebrate excellence in pharmaceutical marketing

The first award of the evening recognised Excellence in Patient Education and Support and went to One Step Further – Resetting Expectations in hATTR Amyloidosis by Alnylam, with support from akt health.

Latest news

DeepMind’s AI tool classifies effects of mutations in genetic diseases

Around 350 million people worldwide are living with rare disorders, approximately 80% of which are genetic in origin, including AA amyloidosis, Adrenoleukodystrophy and Ehlers-Danlos syndrome.
Alnylam's patisiran backed by FDA advisory committee for ATTR cardiomyopathy

ATTR amyloidosis is an underdiagnosed and rapidly progressive disease caused by misfolded transthyretin proteins, which accumulate as amyloid deposits in various parts of the body, including the heart, resulting in cardiomyopathy ... October. Patisiran
Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis

The protein, which is called transthyretin (TTR), can become abnormal in ATTR amyloidosis and break apart into smaller pieces (amyloid). ... for standard of care Onpattro (patisiran), Alnylam’s earlier RNAi ATTRv amyloidosis therapy that is
AstraZeneca and Ionis sign $3.6bn deal for eplontersen

The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition. ... Eplontersen has the potential to halt the progression of TTR-mediated amyloidosis irrespective of
Pfizer's 2021 revenue predictions soar to $82bn

In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased

More from news
Approximately 4 fully matching, plus 43 partially matching documents found.

Latest Intelligence

How telemonitoring can revolutionise the way we treat patients

Remote monitoring in practice. A prominent example of effective remote monitoring can be found in trials for ATTR cardiac amyloidosis (ATTR-CM).
20 for 2020 – Five pharma leaders to watch in 2020

Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... pipeline. The company submitted its lumasiran
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

The drug is licensed to treat to adults with stage 1 or 2 polyneuropathy, the destruction of nerves that results from hereditary transthyretin- mediated (hATTR) amyloidosis, a rare, rapidly progressive, fatal ... The company is working with patient
Tough times for pharma in Portugal

spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis). ... The drug is to be granted marketing approval by the European Medicines Agency for the treatment of

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

What does the future hold for Light-chain Amyloidosis?

What is Light-chain (AL) Amyloidosis? Amyloidosis is a group of rare, serious conditions caused by the abnormal folding of amyloid proteins that build up in tissue throughout the body. ... enhance recognition of AL Amyloidosis itself and the therapies
ASCO 2015: What you missed in Chicago

Three monoclonal antibodies were presented on the last day of ASCO - two in multiple myeloma and one in amyloidosis.
Research Partnership

What does the future hold for Light-chain Amyloidosis?.